India’s Pharma Leaders Head to BIOCHINA 2026
7 January 2026
India’s Pharma Leaders Head to BIOCHINA 2026
This March, BIOCHINA 2026 will bring together global biotech and pharmaceutical leaders in Suzhou, highlighting the accelerating momentum of China–India collaboration in the pharmaceutical sector.
For the first time, India’s top pharmaceutical companies—Sun Pharma, Dr. Reddy’s, and Cipla—have confirmed their participation in BiOPartnering 1V1 meetings, demonstrating their strategic interest in engaging with Chinese innovators and exploring new global growth opportunities.
China and India: Complementary Roles in Global Pharma
China and India are increasingly recognized as complementary players in the global pharmaceutical value chain. China brings strengths in large-scale API production, robust R&D capabilities, and a growing pipeline of innovative therapies. India contributes deep expertise in complex generics, established global commercialization networks, and cost-efficient manufacturing.
This collaboration is already evident in existing partnerships. For example, Henlius Biotech and Dr. Reddy’s have combined their strengths, with Henlius focusing on R&D and manufacturing, while Dr. Reddy’s leverages its commercial networks in Europe and the United States to drive market access.
As competition intensifies in mature markets, Chinese innovation and Indian commercialization capabilities are increasingly converging, creating a fertile landscape for cross-border partnerships. BIOCHINA 2026 provides a platform where these strategic conversations can move from concept to execution.
Spotlight on Participating Indian Pharma Leaders
Sun Pharma is India’s largest pharmaceutical company and the fourth-largest specialty generics company globally. Sun Pharma views China as a key strategic market and deepens engagement through licensing-based collaborations, such as partnerships with Kangzhe Pharma, which holds commercialization rights for multiple products in Greater China.
Dr. Reddy’s was one of the earliest Indian pharmaceutical companies to enter China, establishing its first joint venture in 2000 with Kunshan Rotam Reddy Pharmaceutical. Founded in 1984, the company now operates in over 75 countries, with a portfolio spanning APIs, generics, branded generics, and biosimilars.
Cipla, founded in 1935, operates 46 manufacturing facilities worldwide and markets more than 1,500 products globally. It ranks as India’s third-largest pharmaceutical company and holds the leading position in South Africa’s prescription drug market. Cipla’s China strategy includes a joint venture with Jiangsu Chuangnuo Pharma for inhalation product manufacturing, as well as a wholly owned subsidiary in Shanghai.
In addition to 1V1 meetings, Sun Pharma, Dr. Reddy’s, and Cipla will participate in Main Forum strategic sessions and dedicated China–India collaboration forums, providing multiple opportunities for in-depth dialogue.
Why BIOCHINA 2026 Matters
BIOCHINA 2026 attracts over 30,000 biotech and pharmaceutical professionals on site, including investors, biotech founders, pharma C-level executives, and business development leaders. Structured matchmaking sessions enable efficient engagement for partnerships, projects, and investment opportunities.
Group registration is available. Register five or more BiOPartnering passes and receive 5% off each pass. Once your group registration is confirmed, contact biochina@enmore.com to receive your discount code.
Event Information
Location: Suzhou, China
Date: March 12–14, 2026
Registration: Secure your BiOPartnering pass
Learn more: BIOCHINA 2026 official website